ETON - Eton hits 52-week low as court invalidates patents for generic Cysteine Injection

• The shares of the commercial-stage biopharma Eton Pharmaceuticals ( NASDAQ: ETON ) dropped on Tuesday to reach a 52-week low after a legal setback in its plans to bring a generic version of cysteine hydrochloride injection.
• In an Aug. 08 ruling, a Delaware District Court judge ruled that Eton's ( ETON ) Abbreviated New Drug Application (ANDA) for the product infringed the patent claims of Exela Pharma Sciences, LLC.
• The ruling followed a three-day trial and marked the end of a two-and-a-half-year dispute with Exela.
• The decision is a setback for Eton's ( ETON ) plans to market a generic cysteine hydrochloride injection, sold as Elcys by Exela, for children and liver disease patients requiring total parenteral nutrition.
• In its latest 10-K filing, Eton ( ETON ) said that the current market for Cysteine injection is worth more than $50M annually.

For further details see: